Home > PJ (current issue) > News / Daily News | Search

Return to PJ Online Home Page

The Pharmaceutical Journal
Vol 271 No 7265 p285
6 September 2003

This article
Reprint
Photocopy


News summary

Related websites
Pharmaceutical Price Regulation Scheme discussion paper (more)


Health department launches discussion on the PPRS

The Pharmaceutical Price Regulation Scheme has been opened up for discussion by the Government before it starts negotiations with the Association of the British Pharmaceutical Industry on a replacement.

The PPRS is a non-statutory scheme, agreed between the Government and the ABPI, which indirectly controls the prices of branded prescription medicines to the National Health Service by regulating the profits that companies can make on sales to the NHS. The current scheme has been in force since 1999 and expires in September 2004. The PPRS has existed in various forms since 1957.

The Government is seeking views on whether the current scheme should continue unchanged, what the options for change are, what is the potential for deregulation and any alternative proposals that individuals or organisations might make.

Under the current scheme, all products on the market on 1 October 1999 had their prices cut by 4.5 per cent. Manufacturers can set any price for new products with new active ingredients, but subsequent increases require Government approval. Companies are set a maximum return on capital employed (ROCE) with an allowance for research and development (R&D) costs. Companies with a low capital base are set a maximum return on sales (ROS). If companies fail to achieve this return, that is their problem, but any profits above the maximum have to be returned to the Government.

In a discussion document, the Department of Health asks whether there are any possible alternatives to ROCE and ROS as a basis for the PPRS.

It also wants views on R&D allowances, possible alternatives to the current system for handling transfer pricing between company divisions and allowances for the cost of sales promotions.

The document also suggests that the PPRS could be relaxed, or even abolished, if the NHS can be sure of paying fair and reasonable prices in a deregulated market.

The discussion paper is available on the DoH website. Comments can be sent to

Natacha Deschamps
Medicines Pricing and Supply Branch
Room 138A, Richmond House
79 Whitehall, London SW1A 2NS
e-mail Natacha.Deschamps@doh.gsi.gov.uk

E-mails should be titled “PPRS discussion”.

Back to Top


Home | Journals | News | Notice-board | Search | Jobs  Classifieds | Site Map | Contact us

©The Pharmaceutical Journal